Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
jumped 3.5% in the afternoon session after the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy designation for its drug, sofetabart mipitecan, intended to treat a specific type of ovarian cancer.
NEW BRUNSWICK, N.J. — In a landmark display of resilience and strategic pivoting, Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2025 revenues of $24.56 billion on Wednesday, January 21, 2026, soundly beating Wall Street’s expectations. The healthcare giant accompanied its earnings beat with a bold 2026 financial forecast, projecting
In a move that signals the arrival of the "Bio-Computing" era, NVIDIA (NASDAQ: NVDA) and Eli Lilly (NYSE: LLY) have officially launched a landmark $1 billion AI co-innovation lab. Announced during the J.P. Morgan Healthcare Conference in January 2026, the five-year partnership represents a massive bet on the convergence of generative AI and life sciences. [...]
Eli Lilly's stock is experiencing short-term volatility due to its proximity to a 52-week high and upcoming earnings, amid strong analyst support and mixed technical indicators.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with Zoetis (NYSE:ZTS).
LONDON — January 20, 2026 — In a milestone moment for global capital markets, pharmaceutical giant AstraZeneca (NYSE: AZN) has officially filed its formal notice of voluntary withdrawal from the Nasdaq Stock Market today. The move marks the final countdown for one of the most significant listing migrations in recent history, as
In a move that signals a paradigm shift for the pharmaceutical industry, NVIDIA (NASDAQ: NVDA) and Eli Lilly and Company (NYSE: LLY) have announced the launch of a $1 billion joint AI co-innovation lab. Unveiled on January 12, 2026, during the opening of the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, this landmark [...]
As of January 19, 2026, the pharmaceutical landscape is being redefined by a single name: Eli Lilly and Company (NYSE: LLY). Once a steady, century-old stalwart known for its dominance in the insulin market, Lilly has undergone a metamorphosis, evolving into a $1 trillion cardiometabolic powerhouse. The company’s trajectory has been propelled by a class [...]
As of January 19, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different enterprise than the one most investors recognized just three years ago. Following the successful spin-off of its consumer health division, Kenvue, JNJ has fully transitioned into a high-growth, pure-play healthcare powerhouse focused exclusively on Innovative Medicine and Medical Technology (MedTech). [...]
Join us as we explore Eli Lilly's impressive market position and financial health. Discover why this pharmaceutical giant is capturing investor attention and what the future may hold for its stock.
In a milestone that many researchers are calling the "biological equivalent of the moon landing," AlphaFold 3 has officially moved structural biology into a new era of predictive precision. Developed by Google DeepMind and its commercial sister company, Isomorphic Labs—both subsidiaries of Alphabet Inc. (NASDAQ: GOOGL)—AlphaFold 3 (AF3) has transitioned from a groundbreaking research paper [...]
